Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
$51.04
$46.10
$0.00
$0.00
N/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$54.48
-0.3%
$61.82
$52.56
$74.24
$68.21B0.662.86 million shs4.75 million shs
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$13.89
+0.6%
$16.52
$12.51
$22.80
$15.76B0.729.77 million shs15.18 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
0.00%0.00%0.00%0.00%0.00%
Rio Tinto Group stock logo
RIO
Rio Tinto Group
0.00%-10.39%-12.31%-6.38%-13.25%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.00%-8.14%-9.86%-34.24%-2.95%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
4.3901 of 5 stars
3.53.03.30.04.00.03.8
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.3687 of 5 stars
3.43.00.80.02.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
0.00
N/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
3.00
Buy$73.0033.99% Upside
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.86
Moderate Buy$23.4368.73% Upside

Current Analyst Ratings Breakdown

Latest TEVA, RIO, and RDS-A Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2025
Rio Tinto Group stock logo
RIO
Rio Tinto Group
DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
3/18/2025
Rio Tinto Group stock logo
RIO
Rio Tinto Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
3/6/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$23.00 ➝ $20.00
2/28/2025
Rio Tinto Group stock logo
RIO
Rio Tinto Group
Clarkson Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
1/30/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $27.00
1/30/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$28.00 ➝ $26.00
1/23/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $30.00
1/17/2025
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$23.00 ➝ $30.00
(Data available from 4/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$53.66B1.27$11.35 per share4.80$46.26 per share1.18
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B0.95$2.75 per share5.05$4.75 per share2.92
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/A0.00N/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$10.06B$6.458.438.100.42N/AN/AN/AN/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.45N/A5.281.44-9.91%42.46%6.65%5/7/2025 (Estimated)

Latest TEVA, RIO, and RDS-A Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/29/2025Q4 2024
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$0.69$0.70+$0.01-$0.19$4.10 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
$4.468.19%-14.05%69.15%N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
$1.017.28%N/AN/A N/A

Latest TEVA, RIO, and RDS-A Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/24/2025
Rio Tinto Group stock logo
RIO
Rio Tinto Group
semi-annual$2.237%3/7/20253/7/20254/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
0.23
1.63
1.16
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
2.97
0.98
0.75

Institutional Ownership

CompanyInstitutional Ownership
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
19.33%
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
N/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
N/A
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
0.55%
CompanyEmployeesShares OutstandingFree FloatOptionable
Royal Dutch Shell plc stock logo
RDS-A
Royal Dutch Shell
87,000N/AN/AN/A
Rio Tinto Group stock logo
RIO
Rio Tinto Group
53,7001.25 billionN/AOptionable
Teva Pharmaceutical Industries Limited stock logo
TEVA
Teva Pharmaceutical Industries
36,8001.13 billion1.13 billionOptionable

Recent News About These Companies

Teva announces key developments
Zacks Research Analysts Increase Earnings Estimates for TEVA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Royal Dutch Shell stock logo

Royal Dutch Shell NYSE:RDS-A

Royal Dutch Shell plc operates as an energy and petrochemical company worldwide. The company operates through Integrated Gas, Upstream, Oil Products, Chemicals segments. It explores for and extracts crude oil, natural gas, and natural gas liquids; markets and transports oil and gas; produces gas-to-liquids fuels and other products; and operates upstream and midstream infrastructure necessary to deliver gas to market. The company also markets and trades natural gas, liquefied natural gas (LNG), crude oil, electricity, carbon-emission rights; and markets and sells LNG as a fuel for heavy-duty vehicles and marine vessels. In addition, it trades in and refines crude oil and other feed stocks, such as gasoline, diesel, heating oil, aviation fuel, marine fuel, biofuel, lubricants, bitumen, and sulphur; produces and sells petrochemicals for industrial use; and manages oil sands activities. Further, the company produces base chemicals comprising ethylene, propylene, and aromatics, as well as intermediate chemicals, such as styrene monomer, propylene oxide, solvents, detergent alcohols, ethylene oxide, and ethylene glycol. Royal Dutch Shell plc was founded in 1907 and is headquartered in The Hague, the Netherlands.

Rio Tinto Group stock logo

Rio Tinto Group NYSE:RIO

$54.48 -0.19 (-0.35%)
As of 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rio Tinto Group engages in exploring, mining, and processing mineral resources worldwide. The company operates through Iron Ore, Aluminium, Copper, and Minerals Segments. The Iron Ore segment engages in the iron ore mining, and salt and gypsum production in Western Australia. The Aluminum segment is involved in bauxite mining; alumina refining; and aluminium smelting. The Copper segment engages in mining and refining of copper, gold, silver, molybdenum, and other by-products and exploration activities. The Minerals segment is involved in mining and processing of borates, titanium dioxide feedstock, and iron concentrate and pellets; diamond mining, sorting, and marketing; and development projects for battery materials, such as lithium. It also owns and operates open pit and underground mines; and refineries, smelters, processing plants and power, and shipping facilities. Rio Tinto Group was founded in 1873 and is headquartered in London, the United Kingdom.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$13.88 +0.09 (+0.62%)
As of 03:55 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.